Form 4: ENDRA Life Sciences Director Michael Harsh Granted Restricted Stock Units

Michael Harsh, a Director at ENDRA Life Sciences Inc., was granted 5,384 restricted stock units (RSUs) on June 11, 2025, which will vest in full on June 11, 2026.

Summary

• Michael Harsh, a Director of ENDRA Life Sciences Inc. (NDRA), was granted 5,384 restricted stock units (RSUs).
• The grant date for these RSUs was June 11, 2025.
• These RSUs convert to common stock on a one-for-one basis and will vest in full on June 11, 2026.
• The acquisition price for these RSUs was $0.
• Following this transaction, Michael Harsh's direct beneficial ownership of ENDRA Life Sciences common stock is 5,386 shares.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a routine equity compensation event that aligns the director's interests with shareholder value, generally viewed as a neutral to slightly positive development for corporate governance and long-term commitment.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, as the value of the RSUs is tied to the company's stock performance.
• The acquisition of 5,384 RSUs at a $0 price represents a form of equity compensation, which can incentivize long-term commitment and performance.

Negatives

• No specific negative financial or operational information is contained in this Form 4 filing.

Risks

• The document itself does not detail specific risks to the company's operations or financial health. The primary risk related to RSUs is that their value is dependent on the future stock price, which can fluctuate.

Future Outlook

The restricted stock units granted to Director Michael Harsh are scheduled to vest in full on June 11, 2026, indicating a future milestone for this equity compensation.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

This Form 4 filing reports a standard equity compensation grant to a director, a common practice across industries to align executive and board member interests with shareholder value. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• This transaction is a routine grant of restricted stock units to a director, which is a common form of equity compensation in publicly traded companies across various sectors, including life sciences. Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual insider transaction.

Related Party Transactions

• The filing reports the grant of 5,384 restricted stock units to Michael Harsh, a Director of ENDRA Life Sciences Inc., as a form of equity compensation.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can be seen as positive for shareholders as it aligns the director's financial interests with the company's long-term stock performance.

Next Steps

• The 5,384 restricted stock units will vest in full on June 11, 2026.

Key Dates

Keywords

ENDRA Life Sciences, NDRA, Restricted Stock Units, RSUs, Insider Transaction, Form 4, Director Compensation, Equity Grant, Michael Harsh